Skip to main content

Advertisement

SpringerLink
Log in

IBD in children: Lessons for adults

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

When children develop inflammatory bowel disease (IBD), physicians and researchers are presented with a singular opportunity to understand the nature of these chronic, idiopathic illnesses in the earliest stages. Genetic susceptibility factors tend to be common, whereas complicating environmental factors such as cigarette smoking are generally not an issue. As opposed to the case in adult patients, Crohn’s disease is usually diagnosed in children at an early, inflammatory phase of the disease. Pediatric ulcerative colitis tends to present with more severe and more extensive involvement than in adults. In both forms of IBD, the severity of disease activity often dictates the need for early aggressive nutritional, immunomodulatory, and biologic therapy. As a result, the lessons learned from the evaluation and treatment of children with IBD are critically important to the clinician caring for adults with the same disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Auvin S, Molinie F, Gower-Rousseau C, et al.: Incidence, clinical presentation and location at diagnosis of pediatric inflammatory bowel disease: a prospective population-based study in Northern France (1988–1999). J Pediatr Gastroenterol Nutr 2005, 41:49–55.

    Article  PubMed  Google Scholar 

  2. Devadason D, Hussien H, Spray C, et al.: The incidence of ulcerative colitis has doubled since 1999 [abstract]. J Pediatr Gastroenterol Nutr 2005, 40:642

    Google Scholar 

  3. Kugathasan S, Judd RH, Hoffman RG, et al.: Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr 2003, 143:525–531.

    Article  PubMed  Google Scholar 

  4. Griffiths AM: Specificities of inflammatory bowel disease in children. Best Pract Res Clin Gastroenterol 2004, 18:509–523.

    Article  PubMed  Google Scholar 

  5. Ogunbi SO, Ransom JA, Sullivan K, et al.: Inflammatory bowel disease in African-American children living in Georgia. J Pediatr 1998, 133:103–107.

    Article  PubMed  CAS  Google Scholar 

  6. Kugathasan S, Collins N, Maresso K, et al.: CARD15 gene mutations and the risk for early surgery in pediatric-onset Crohn’s disease. Clin Gastroenterol Hepatol 2004, 2:1003–1009.

    Article  PubMed  CAS  Google Scholar 

  7. Russell RK, Drummond HE, Nimmo EE, et al.: Genotypephenotype analysis in childhood-onset Crohn’s disease: NOD2/CARD15 variants consistently predict phenotypic characteristics of severe disease. Inflamm Bowel Dis 2005, 11:955–964.

    Article  PubMed  Google Scholar 

  8. Rioux JD, Silverberg MS, Daly MJ, et al.: Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am J Hum Genet 2000, 66:1863–1870.

    Article  PubMed  CAS  Google Scholar 

  9. Cucchiara S, Latiano A, Palmieri O, et al.: Polymorphisms to tumor necrosis factor-alpha but not MDR1 influence response to medical therapy in pediatric-onset inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007, 44:171–179.

    PubMed  CAS  Google Scholar 

  10. Sawczenko A, Azooz O, Paraszczuk J, et al.: Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the-174 IL-6 G/C polymorphism in children. Proc Nat Acad Sci U S A 2005, 102:13260–13265.

    Article  CAS  Google Scholar 

  11. Zhouldev A, Zurakowski D, Young W, et al.: Serologic testing with ANCA, ASCA, and Anti-OmpC in children and young adults with Crohn’s disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol 2004, 99:2235–2241.

    Article  Google Scholar 

  12. Dubinsky M, Lin-Chao L, Dutridge D, et al.: Serum immune responses predict rapid disease progression among children with Crohn’s disease: immune responses predict disease progression. Am J Gastroenterol 2006, 101:360–367.

    Article  PubMed  Google Scholar 

  13. Amre DK, Lu SE, Seidman EG, et al.: Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn’s disease patients. Am J Gastroenterol 2006, 101:645–652.

    Article  PubMed  Google Scholar 

  14. Markowitz J, Grancher K, Kohn N, Daum F: Immunomodulatory therapy for pediatric inflammatory bowel disease: changing patterns of use, 1990–2000. Am J Gastroenterol 2002, 97:928–932.

    PubMed  Google Scholar 

  15. Hyams J, Markowitz J, Lerer T, et al.: The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol 2006, 4:1118–1123.

    Article  PubMed  CAS  Google Scholar 

  16. Faubion WA, Jr, Loftus EV, Jr, Harmsen WS, et al.: The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001, 121:255–260.

    Article  PubMed  CAS  Google Scholar 

  17. Markowitz J, Grancher K, Kohn N, et al.: A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology 2000, 119:895–902.

    Article  PubMed  CAS  Google Scholar 

  18. Markowitz J, Hyams J, Mack D, et al.: Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn’s disease. Clin Gastroenterol Hepatol 2006, 4:1124–1129.

    Article  PubMed  CAS  Google Scholar 

  19. Ballinger AB, Azooz O, El-Haj T: Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis. Gut 2000, 46:695–700.

    Article  Google Scholar 

  20. Bannaerjee K, Camacho-Hubner C, Babinska K, et al.: Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn disease. J Pediatr Gastroenterol Nutr 2004, 38:270–275.

    Article  Google Scholar 

  21. Johnson T, Macdonald S, Hill SM, et al.: Treatment of active Crohn’s disease in children using partial enteral nutrition with liquid formula: a randomized controlled trial. Gut 2006, 55:356–361.

    Article  PubMed  CAS  Google Scholar 

  22. Borrelli O, Cordischi L, Circulli M, et al.: Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn’s disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol 2006, 4:744–753.

    Article  PubMed  Google Scholar 

  23. Griffiths AM, Ohlsson A, Sherman PM, et al.: Meta-analysis of enteral nutrition as the primary treatment of active Crohn’s disease. Gastroenterology 1995, 108:1056–1067.

    Article  PubMed  CAS  Google Scholar 

  24. Canini RB, Terrin G, Borrelli O, et al.: Short-and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn’s disease. Dig Liver Dis 2006, 38:381–387.

    Article  CAS  Google Scholar 

  25. Sediman EG, Lohoues MJ, Turgeon J, et al.: Elemental diet versus prednisone as initial therapy in Crohn’s disease: early and long-term results [abstract]. Gastroenterology 1991, 100:250A.

    Google Scholar 

  26. Jacobstein DA, Mamula P, Markowitz JE, et al.: Predictors of immunomodulator use as early therapy in pediatric Crohn’s disease. J Clin Gastroenterol 2006, 40:145–148.

    Article  PubMed  CAS  Google Scholar 

  27. Dubinsky MC, Lamothe S, Yang HY, et al.: Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000, 118:705–713.

    Article  PubMed  CAS  Google Scholar 

  28. Dubinsky MC, Yang H, Hassard PV, et al.: 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002, 122:904–915.

    Article  PubMed  CAS  Google Scholar 

  29. Banerjee S, Bishop W: Evolution of thiopurine use in pediatric inflammatory bowel disease in an academic center: role of thiopurine methyltransferase and 6-mercaptopurine metabolite measurements. J Pediatr Gastroenterol Nutr 2006, 43:324–330.

    Article  PubMed  CAS  Google Scholar 

  30. Hyams JS, Markowitz J, Robert W: Use of infliximab in the treatment of Crohn’s disease in children and adolescents. J Pediatr 2000, 137:192–196.

    Article  PubMed  CAS  Google Scholar 

  31. Kugathasan S, Werlin S, Martinez A, et al.: Prolonged duration of response to infliximab in early but not late pediatric Crohn’s disease. Am J Gastroenterol 2000, 95:3189–3194.

    Article  PubMed  CAS  Google Scholar 

  32. Baldassano R, Braegger CP, Escher JC, et al.: Infliximab (REMICADE) therapy in the treatment of pediatric Crohn’s disease. Am J Gastroenterol 2003, 98:833–838.

    Article  PubMed  CAS  Google Scholar 

  33. Hyams J, Crandall W, Kugathasan S, et al.: Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology 2007, 132:863–873.

    Article  PubMed  CAS  Google Scholar 

  34. Mamula P, Markowitz JE, Cohen LJ, et al.: Infliximab in pediatric ulcerative colitis: two-year follow-up. J Pediatr Gastroenterol Nutr 2004, 38:298–301.

    Article  PubMed  CAS  Google Scholar 

  35. Friesen CA, Calabro C, Christenson K, et al.: Safety of infliximab treatment in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2004, 39:265–269.

    Article  PubMed  CAS  Google Scholar 

  36. Mackey AC, Green L, Liang LC: Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007, 44:265–267.

    Article  PubMed  Google Scholar 

  37. Summers RW, Switz DM, Sessions JT, et al.: National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology 1979, 77:847–869.

    PubMed  CAS  Google Scholar 

  38. Malchow H, Ewe K, Brandes JW, et al.: European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984, 86:249–266.

    PubMed  CAS  Google Scholar 

  39. Alemzadeh N, Rekers-Mombarg LT, Mearin ML: Adult height in patients with early-onset Crohn’s disease. Gut 2002, 51:26–29.

    Article  PubMed  CAS  Google Scholar 

  40. Kirschner BS: Growth and development in chronic inflammatory bowel disease. Acta Pediatr Scand Suppl 1990 366:98–104.

    CAS  Google Scholar 

  41. Markowitz J, Grancher K, Rosa J, et al.: Growth failure in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1993, 16:373–380.

    Article  PubMed  CAS  Google Scholar 

  42. Freeman HJ: Application of the Vienna Classification for Crohn’s disease to a single clinician database of 877 patients. Can J Gastroenterol 2001, 15:89–93.

    PubMed  CAS  Google Scholar 

  43. Freeman HJ: Long-term prognosis of early-onset Crohn’s disease diagnosed in childhood or adolescence. Can J Gastroenterol 2004, 18:661–665.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Schneider Children’s Hospital, 269-01 76th Avenue, CH-234, New Hyde Park, NY, 11040, USA

    Cindy A. Haller

Authors
  1. Cindy A. Haller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James Markowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cindy A. Haller.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Haller, C.A., Markowitz, J. IBD in children: Lessons for adults. Curr Gastroenterol Rep 9, 528–532 (2007). https://doi.org/10.1007/s11894-007-0070-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-007-0070-8

Keywords

Search

Navigation